Ghost Tree Capital
Latest statistics and disclosures from Ghost Tree Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, SRPT, XBI, AKRO, KRYS, and represent 34.78% of Ghost Tree Capital's stock portfolio.
- Added to shares of these 10 stocks: MLTX (+$14M), SRPT (+$13M), IMVT (+$8.3M), KRYS (+$7.0M), RCKT, TARS, TSHA, DCPH, REPL, SLRN.
- Started 18 new stock positions in DCPH, CYTK, KALV, ABOS, SLRN, CBAY, GPCR, IMVT, ACAD, TVTX. MOR, ARGX, ETNB, TSHA, EYPT, LEGN, VTYX, CRNX.
- Reduced shares in these 10 stocks: Reata Pharmaceuticals Inc Cl A (-$8.7M), PCVX (-$7.1M), AMLX (-$6.1M), MRTX (-$6.1M), VKTX, , BGNE, VIR, XENE, RVNC.
- Sold out of its positions in BGNE, BCRX, BTAI, FGEN, INCY, IOVA, MORF, PTCT, Reata Pharmaceuticals Inc Cl A, SWTX. VNDA, VIR.
- Ghost Tree Capital was a net buyer of stock by $57M.
- Ghost Tree Capital has $304M in assets under management (AUM), dropping by 0.38%.
- Central Index Key (CIK): 0001595851
Tip: Access up to 7 years of quarterly data
Positions held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Ghost Tree Capital
Ghost Tree Capital holds 63 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 10.9 | $33M | +75% | 580k | 57.00 |
|
Sarepta Therapeutics (SRPT) | 7.6 | $23M | +123% | 190k | 121.22 |
|
Spdr Ser Tr S&p Biotech Call Option (XBI) | 7.2 | $22M | 300k | 73.02 |
|
|
Akero Therapeutics (AKRO) | 6.1 | $19M | 365k | 50.58 |
|
|
Krystal Biotech (KRYS) | 3.1 | $9.3M | +300% | 80k | 116.00 |
|
Madrigal Pharmaceuticals (MDGL) | 2.8 | $8.4M | +4% | 58k | 146.04 |
|
Tg Therapeutics (TGTX) | 2.7 | $8.4M | +21% | 1.0M | 8.36 |
|
Immunovant (IMVT) | 2.7 | $8.3M | NEW | 215k | 38.39 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 2.6 | $8.0M | -15% | 85k | 93.64 |
|
Axsome Therapeutics (AXSM) | 2.5 | $7.7M | 110k | 69.89 |
|
|
Alpine Immune Sciences (ALPN) | 2.5 | $7.6M | +91% | 664k | 11.45 |
|
Syndax Pharmaceuticals (SNDX) | 2.4 | $7.3M | +42% | 500k | 14.52 |
|
Vaxcyte (PCVX) | 2.3 | $7.1M | -50% | 140k | 50.98 |
|
Tarsus Pharmaceuticals (TARS) | 2.3 | $7.1M | +166% | 400k | 17.77 |
|
Apellis Pharmaceuticals Call Option (APLS) | 2.3 | $7.0M | +2% | 185k | 38.04 |
|
Protagonist Therapeutics (PTGX) | 2.2 | $6.7M | +77% | 400k | 16.68 |
|
Cogent Biosciences (COGT) | 2.1 | $6.3M | +13% | 650k | 9.75 |
|
Rocket Pharmaceuticals Call Option (RCKT) | 2.0 | $6.0M | +293% | 295k | 20.49 |
|
Ambrx Biopharma Sponsored Ads | 2.0 | $6.0M | +120% | 525k | 11.50 |
|
Pmv Pharmaceuticals (PMVP) | 1.4 | $4.3M | +151% | 706k | 6.14 |
|
Replimune Group Call Option (REPL) | 1.4 | $4.3M | +2200% | 250k | 17.11 |
|
Miragen Therapeutics (VRDN) | 1.4 | $4.2M | +14% | 275k | 15.34 |
|
Taysha Gene Therapies Com Shs (TSHA) | 1.4 | $4.2M | NEW | 1.3M | 3.16 |
|
Deciphera Pharmaceuticals (DCPH) | 1.4 | $4.1M | NEW | 325k | 12.72 |
|
Phathom Pharmaceuticals (PHAT) | 1.3 | $4.1M | +156% | 395k | 10.37 |
|
Acelyrin (SLRN) | 1.3 | $4.1M | NEW | 400k | 10.17 |
|
Revance Therapeutics (RVNC) | 1.3 | $4.0M | -33% | 350k | 11.47 |
|
Amylyx Pharmaceuticals (AMLX) | 1.3 | $3.9M | -60% | 215k | 18.31 |
|
Cymabay Therapeutics Call Option (CBAY) | 1.2 | $3.5M | NEW | 238k | 14.91 |
|
Xenon Pharmaceuticals (XENE) | 1.1 | $3.4M | -46% | 99k | 34.16 |
|
Crinetics Pharmaceuticals In (CRNX) | 1.0 | $3.0M | NEW | 101k | 29.74 |
|
ImmunoGen (IMGN) | 0.9 | $2.8M | +75% | 175k | 15.87 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 0.9 | $2.8M | NEW | 55k | 50.42 |
|
Aerovate Therapeutics (AVTE) | 0.9 | $2.7M | 201k | 13.57 |
|
|
Morphosys Sponsored Ads (MOR) | 0.9 | $2.7M | NEW | 400k | 6.72 |
|
Cytokinetics Com New (CYTK) | 0.9 | $2.7M | NEW | 90k | 29.46 |
|
Mirati Therapeutics (MRTX) | 0.9 | $2.6M | -70% | 60k | 43.56 |
|
Eyepoint Pharmaceuticals Com New (EYPT) | 0.9 | $2.6M | NEW | 325k | 7.99 |
|
Viking Therapeutics (VKTX) | 0.8 | $2.5M | -65% | 225k | 11.07 |
|
Astria Therapeutics (ATXS) | 0.7 | $2.2M | 300k | 7.46 |
|
|
Amicus Therapeutics (FOLD) | 0.7 | $2.1M | -12% | 175k | 12.16 |
|
Karuna Therapeutics Ord (KRTX) | 0.7 | $2.1M | 13k | 169.09 |
|
|
Zentalis Pharmaceuticals (ZNTL) | 0.7 | $2.0M | 100k | 20.06 |
|
|
Bridgebio Pharma (BBIO) | 0.7 | $2.0M | +78% | 75k | 26.37 |
|
ACADIA Pharmaceuticals (ACAD) | 0.5 | $1.7M | NEW | 80k | 20.84 |
|
Legend Biotech Corp Sponsored Ads (LEGN) | 0.5 | $1.5M | NEW | 23k | 67.17 |
|
Uniqure Nv SHS (QURE) | 0.5 | $1.4M | 215k | 6.71 |
|
|
Arcus Biosciences Incorporated (RCUS) | 0.4 | $1.3M | 75k | 17.95 |
|
|
Travere Therapeutics (TVTX) | 0.4 | $1.3M | NEW | 150k | 8.94 |
|
Argenx Se Sponsored Adr (ARGX) | 0.4 | $1.2M | NEW | 2.5k | 491.63 |
|
Ventyx Biosciences (VTYX) | 0.4 | $1.2M | NEW | 35k | 34.73 |
|
Aadi Bioscience (AADI) | 0.4 | $1.2M | 250k | 4.84 |
|
|
Kalvista Pharmaceuticals (KALV) | 0.3 | $963k | NEW | 100k | 9.63 |
|
Biomea Fusion (BMEA) | 0.3 | $894k | -65% | 65k | 13.76 |
|
Roivant Sciences SHS (ROIV) | 0.2 | $748k | 64k | 11.68 |
|
|
Verona Pharma Sponsored Ads (VRNA) | 0.2 | $734k | -59% | 45k | 16.30 |
|
Inhibrx (INBX) | 0.2 | $642k | 35k | 18.35 |
|
|
Fusion Pharmaceuticals (FUSN) | 0.2 | $633k | -41% | 243k | 2.60 |
|
Acumen Pharmaceuticals (ABOS) | 0.2 | $623k | NEW | 150k | 4.15 |
|
89bio (ETNB) | 0.2 | $463k | NEW | 30k | 15.44 |
|
Avidity Biosciences Ord (RNA) | 0.1 | $415k | 65k | 6.38 |
|
|
Rain Therapeutics (RAIN) | 0.1 | $280k | 325k | 0.86 |
|
|
Mersana Therapeutics (MRSN) | 0.0 | $78k | 61k | 1.27 |
|
Past Filings by Ghost Tree Capital
SEC 13F filings are viewable for Ghost Tree Capital going back to 2013
- Ghost Tree Capital 2023 Q3 filed Nov. 14, 2023
- Ghost Tree Capital 2023 Q2 filed Aug. 14, 2023
- Ghost Tree Capital 2023 Q1 filed May 15, 2023
- Ghost Tree Capital 2022 Q4 filed Feb. 14, 2023
- Ghost Tree Capital 2022 Q3 filed Nov. 14, 2022
- Ghost Tree Capital 2022 Q2 filed Aug. 15, 2022
- Ghost Tree Capital 2022 Q1 filed May 16, 2022
- Ghost Tree Capital 2021 Q4 filed Feb. 16, 2022
- Ghost Tree Capital 2021 Q3 filed Nov. 15, 2021
- Ghost Tree Capital 2021 Q1 restated filed Aug. 11, 2021
- Ghost Tree Capital 2021 Q2 filed Aug. 11, 2021
- Ghost Tree Capital 2021 Q1 filed May 14, 2021
- Ghost Tree Capital 2020 Q4 restated filed Feb. 18, 2021
- Ghost Tree Capital 2020 Q4 filed Feb. 16, 2021
- Ghost Tree Capital 2020 Q3 filed Nov. 16, 2020
- Ghost Tree Capital 2020 Q2 filed Aug. 14, 2020